Vanguard Group Inc. Has $65.40 Million Stock Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Vanguard Group Inc. lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 2.7% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 2,282,666 shares of the specialty pharmaceutical company's stock after selling 63,876 shares during the period. Vanguard Group Inc. owned approximately 7.08% of Collegium Pharmaceutical worth $65,398,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in COLL. FMR LLC lifted its holdings in shares of Collegium Pharmaceutical by 1,532.2% during the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company's stock worth $1,459,000 after buying an additional 35,439 shares during the last quarter. Verition Fund Management LLC increased its stake in Collegium Pharmaceutical by 35.1% during the third quarter. Verition Fund Management LLC now owns 14,042 shares of the specialty pharmaceutical company's stock valued at $543,000 after acquiring an additional 3,652 shares during the period. Janus Henderson Group PLC raised its holdings in Collegium Pharmaceutical by 399.4% in the 3rd quarter. Janus Henderson Group PLC now owns 69,485 shares of the specialty pharmaceutical company's stock valued at $2,686,000 after acquiring an additional 55,572 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Collegium Pharmaceutical by 17.2% in the 3rd quarter. Wellington Management Group LLP now owns 114,640 shares of the specialty pharmaceutical company's stock worth $4,430,000 after acquiring an additional 16,784 shares during the period. Finally, Barclays PLC grew its holdings in shares of Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after purchasing an additional 45,291 shares in the last quarter.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages recently commented on COLL. Needham & Company LLC restated a "buy" rating and issued a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research note on Tuesday, February 4th. StockNews.com upgraded shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research report on Friday. Finally, HC Wainwright reissued a "buy" rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Collegium Pharmaceutical has a consensus rating of "Buy" and an average price target of $43.60.

Insider Activity at Collegium Pharmaceutical

In other news, EVP Scott Dreyer sold 2,255 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the transaction, the executive vice president now directly owns 124,421 shares in the company, valued at approximately $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Shirley R. Kuhlmann sold 26,067 shares of the stock in a transaction that occurred on Thursday, March 6th. The shares were sold at an average price of $28.50, for a total transaction of $742,909.50. Following the sale, the executive vice president now directly owns 108,137 shares in the company, valued at $3,081,904.50. This trade represents a 19.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 81,693 shares of company stock valued at $2,334,994 in the last three months. Corporate insiders own 3.98% of the company's stock.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL traded up $0.19 on Tuesday, hitting $26.92. The stock had a trading volume of 169,841 shares, compared to its average volume of 442,992. The firm's 50 day moving average price is $29.06 and its 200-day moving average price is $31.47. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The company has a market capitalization of $864.99 million, a price-to-earnings ratio of 11.60 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, equities research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.